Interface of signal transduction inhibition and immunotherapy in melanoma.
about
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma riskChanges of PI3K/AKT/BCL2 signaling proteins in congenital Giant Nevi: melanocytes contribute to their increased survival and integrity.
P2860
Interface of signal transduction inhibition and immunotherapy in melanoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Interface of signal transduction inhibition and immunotherapy in melanoma.
@ast
Interface of signal transduction inhibition and immunotherapy in melanoma.
@en
type
label
Interface of signal transduction inhibition and immunotherapy in melanoma.
@ast
Interface of signal transduction inhibition and immunotherapy in melanoma.
@en
prefLabel
Interface of signal transduction inhibition and immunotherapy in melanoma.
@ast
Interface of signal transduction inhibition and immunotherapy in melanoma.
@en
P2860
P1433
P1476
Interface of signal transduction inhibition and immunotherapy in melanoma.
@en
P2093
Amber L Shada
Kerrington R Molhoek
P2860
P304
P356
10.1097/PPO.0B013E3181EB3393
P577
2010-07-01T00:00:00Z